Recent advances in cancer immunotherapy have demonstrated unprecedented clinical benefits, offering hope of long-term remission—and even cure—for patients with advanced cancers. In step with this transformation in patient care, mediSMART is proud to be at the forefront of the evolving landscape of oncology drug development.

Our oncology research portfolio includes early-phase to late-phase clinical studies across a wide range of solid and hematological malignancies, such as:

🎗️ Breast cancer

🫁 Lung cancer

🔬 Gastric cancer

🧬 Hepatocellular carcinoma (HCC)

⚕️ Prostate cancer

🩸 Multiple myeloma

🔴 Acute myeloid leukemia (AML)

💉 Lymphoma

🧪 Leukaemia

With a strong network of investigators, study coordinators, and oncology experts, we support global sponsors and CROs in accelerating clinical trials with quality, speed, and regulatory compliance—from site selection to patient recruitment and study management.